Modulari-T
ActiveWe teach your immune system to attack and cure cancer
About
Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.
Founders · 2
David is the CEO and cofounder of Modulari-T. His expertise spans multiple areas and he is driven by a passion for pushing the boundaries of technology. During his PhD he discovered how protein receptors form complex structures that allow them to alter cells’ behavior. He then took this knowledge and the novel technology that was developed to build Modulari-T. When he’s not thinking up a new way to engineer cells he can be spotted biking or running up a mountain.
Co-founder and COO at Modulari-T. PhD in chemical engineering. Technical background in synthetic biology, advanced 3D cell culture systems, and biomaterials in the context of the cellular cancer microenvironment. Fascinated by the innovations cell-based therapies, food products, and the scale up of their manufacturing. Gave the unconference talk "Lessons learned and mistakes made growing the world's hottest peppers".
Launch
We teach your immune system to attack and cure cancer.
Modulari-T is a cell therapy company that uses the Modular Actuation Receptor Complex (MARC) platform to reprogram immune cells to recognize cancer antigens, aiming for higher tumor clearance with fewer side effects. They announce MARC enables cancer treatment and broader applications beyond oncology, and invite partnerships and hires.
From the original launch (Jan 2023) — may be outdated.
Formerly “Modulari-T Biosciences”
Related startups
Dendritic cell-based platform for cancer therapy
Reprogramming Immunity for Target-Specific Medicines
